nach oben

Erschienen in:

02.08.2017 | Original Article

Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis

verfasst von: Jan-Christopher Metzger, Dr. Daniel Wollschläger, PD Dr. Matthias Miederer, Prof. Dr. Peter Vaupel, Prof. Dr. Markus Moehler, Prof. Dr. Heinz Schmidberger, PD Dr. Arnulf Mayer

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

PET-CT is widely used for both the staging and planning of primary or neoadjuvant chemoradiotherapy for esophageal cancer. Inclusion of PET-CT information into radiotherapy planning often leads to substantial modifications of the target volume. In the case of detection of distant metastases, it may also result in a switch to a palliative treatment approach. This spares patients from therapy-related toxicities that provide no clinical benefit. However, due to a lack of studies, it is currently unclear whether the advantages of PET-CT also translate into a measurable improvement in patient survival.

Patients and methods

A retrospective analysis assessed the survival data of 145 patients with esophageal carcinoma stages I (eight patients; 5%), II (45; 31%), III (79; 55%), IV (8; 5%) and unknown (5; 4%). Patients were treated between 1999 and 2014 either with primary chemoradiation (n = 101) or neoadjuvant chemoradiation at the Department of Radiation Oncology, University Medical Center Mainz, followed by transabdominal or transthoracic tumor resection (n = 44). Of the 145 patients, 64 (44%) had undergone PET-CT.

Results

Univariate analysis showed the use of PET-CT to be associated with significantly longer local recurrence-free survival (p = 0.006) and tended to translate into a measurable improvement of overall survival (p = 0.071). Since more patients underwent surgery in the group planned using PET-CT (20% vs. 44%; p = 0.002), we carried out a multivariate Cox regression analysis to adjust for this possible confounding factor. Surgery (p = 0.042; HR 0.55; 95% confidence interval: 0.31–0.98) as well as the use of PET-CT (p = 0.048; HR 0.60; 95% confidence interval: 0.36–0.99) nearly halved the risk of local recurrence. It was only in the group of patients with PET-CT that a trend towards a shorter overall survival was evident in lymph node-positive patients (p = 0.16), whereas nodal stage did not impact on survival in patients staged without PET-CT (p = 0.97).

Conclusion

To the best of our knowledge these data suggest for the first time that the use of PET-CT in the framework of staging and planning of primary or neoadjuvant chemoradiotherapy for esophageal cancer has a favorable impact on patient survival.

World Health Organisation (2012) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012

Earlam R, Cunha-Melo JR (1980) Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67(6):381–390CrossRefPubMed

van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ, Groen H, Plukker JT (2004) Systematic review of the staging performance of 18 F-fluorodeoxyglucose positron emission tomography in esophageal cancer. Journal of clinical oncology : official journal of the American Society of. Clin Oncol 22(18):3805–3812. doi:10.1200/JCO.2004.01.083 CrossRef

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, (IQWiG) (2013) Positronenemissionstomographie (PET) und PET/CT bei Ösophaguskarzinom. Abschlussbericht D06-01H. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Köln

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. doi:10.1056/NEJMoa1112088 CrossRefPubMed

Liu S, Zhu H, Li W, Zhang B, Ma L, Guo Z, Huang Y, Song P, Yu J, Guo H (2016) Potential impact of (18)FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagus. Onco Targets Ther 9:855–862. doi:10.2147/OTT.S97896 PubMedPubMedCentral

Lammering G, De Ruysscher D, van Baardwijk A, Baumert BG, Borger J, Lutgens L, van den Ende P, Ollers M, Lambin P (2010) The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 186(9):471–481. doi:10.1007/s00066-010-2150-1 CrossRefPubMed

Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ (2013) Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119(6):1149–1158. doi:10.1002/cncr.27834 CrossRefPubMed

Park SY, Kim DJ, Jung HS, Yun MJ, Lee JW, Park CK (2015) Relationship between the size of metastatic lymph nodes and positron emission tomographic/computer tomographic findings in patients with esophageal squamous cell carcinoma. World J Surg 39(12):2948–2954. doi:10.1007/s00268-015-3221-3 CrossRefPubMed

10.

Schreurs LM, Busz DM, Paardekooper GM, Beukema JC, Jager PL, van der Jagt EJ, van Dam GM, Groen H, Plukker JT, Langendijk JA (2010) Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition. Dis Esophagus 23(6):493–501. doi:10.1111/j.1442-2050.2009.01044.x CrossRefPubMed

11.

Muijs CT, Beukema JC, Woutersen D, Mul VE, Berveling MJ, Pruim J, van der Jagt EJ, Hospers GA, Groen H, Plukker JT, Langendijk JA (2014) Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. Radiother Oncol 113(2):188–192. doi:10.1016/j.radonc.2014.10.016 CrossRefPubMed

12.

Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr., Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA (2004) 2‑Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776–1785. doi:10.1002/cncr.20585 CrossRefPubMed

13.

Thomas L, Lapa C, Bundschuh RA, Polat B, Sonke JJ, Guckenberger M (2015) Tumour delineation in oesophageal cancer – a prospective study of delineation in PET and CT with and without endoscopically placed clip markers. Radiother Oncol 116(2):269–275. doi:10.1016/j.radonc.2015.07.007 CrossRefPubMed

14.

Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22(5):900–908. doi:10.1200/JCO.2004.07.122 CrossRefPubMed

15.

van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253(1):56–63. doi:10.1097/SLA.0b013e3181f66596 CrossRefPubMed

16.

Chen H, Li Y, Wu H, Sun L, Lin Q, Zhao L, An H (2015) 3’-deoxy-3’-[(1)(8)F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [(1)(8)F]-FDG PET/CT. Strahlenther Onkol 191(2):141–152. doi:10.1007/s00066-014-0744-8 CrossRefPubMed

17.

Ordu AD, Nieder C, Geinitz H, Kup PG, Deymann LF, Scherer V, Combs SE, Fakhrian K (2015) Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome. Strahlenther Onkol 191(2):153–160. doi:10.1007/s00066-014-0779-x CrossRefPubMed

18.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2015) S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adeno- karzinome des Ösophagus, Langversion 1.0, AWMF Registernummer: 021/023OL. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html. Accessed 04/07/2017

19.

Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, Meltzer CC (1999) Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 68(4):1133–1136 (discussion 1136–1137)CrossRefPubMed

20.

Flamen P, Lerut A, van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. Journal of clinical oncology: official journal of the American Society of clinical oncology. Clin Oncol 18(18):3202–3210CrossRef

21.

Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94(4):921–928CrossRefPubMed

22.

Kneist W, Schreckenberger M, Bartenstein P, Grunwald F, Oberholzer K, Junginger T (2003) Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg 27(10):1105–1112. doi:10.1007/s00268-003-6921-z CrossRefPubMed

23.

Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45(6):980–987PubMed

24.

van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98(3):547–557. doi:10.1038/sj.bjc.6604200 CrossRefPubMedPubMedCentral

25.

Hsu WH, Hsu PK, Wang SJ, Lin KH, Huang CS, Hsieh CC, Wu YC (2009) Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg 87(5):1564–1568. doi:10.1016/j.athoracsur.2009.02.065 CrossRefPubMed

26.

Noble F, Bailey D, Panel SUGT, Tung K, Byrne JP (2009) Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 64(7):699–705. doi:10.1016/j.crad.2009.03.003 CrossRefPubMed

27.

Anderegg MC, de Groof EJ, Gisbertz SS, Bennink RJ, Lagarde SM, Klinkenbijl JH, Dijkgraaf MG, Bergman JJ, Hulshof MC, van Laarhoven HW, van Berge Henegouwen MI (2015) 18 F-FDG PET-CT after neoadjuvant chemoradiotherapy in esophageal cancer patients to optimize surgical decision making. PLoS ONE 10(11):e0133690. doi:10.1371/journal.pone.0133690 CrossRefPubMedPubMedCentral

Titel: Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis
verfasst von: Jan-Christopher Metzger
Dr. Daniel Wollschläger
PD Dr. Matthias Miederer
Prof. Dr. Peter Vaupel
Prof. Dr. Markus Moehler
Prof. Dr. Heinz Schmidberger
PD Dr. Arnulf Mayer
Publikationsdatum: 02.08.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1164-3

Springer Medizin

Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis